Cargando…

COVID-19 and blood cancer in the vaccination era

Detalles Bibliográficos
Autores principales:	Hicks, Lisa K., Vijenthira, Abi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by The American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906371/ https://www.ncbi.nlm.nih.gov/pubmed/36580343 http://dx.doi.org/10.1182/blood.2022018396

Ejemplares similares

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
por: Niemann, Carsten U., et al.
Publicado: (2022)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19
por: Hoiland, Ryan L., et al.
Publicado: (2020)

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
por: Pagano, Livio, et al.
Publicado: (2022)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
por: Herishanu, Yair, et al.
Publicado: (2021)

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
por: Herishanu, Yair, et al.
Publicado: (2022)

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
por: Perry, C., et al.
Publicado: (2021)

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
por: La Mura, Vincenzo, et al.
Publicado: (2023)

COVID-19, plasma, and hypogammaglobulinemia
por: Murphy, Michael F., et al.
Publicado: (2020)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

When CLL meets COVID-19
por: Montserrat, Emili
Publicado: (2020)

COVID-19 Vaccine Response in Patients with Hematologic Malignancy: A Systematic Review and Meta-Analysis
por: Gong, Inna, et al.
Publicado: (2021)

Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival
por: Martinez, Caridad, et al.
Publicado: (2022)

COVID-19 and SCA: an old friend comes to the rescue
por: Novelli, Enrico M.
Publicado: (2020)

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
por: van Doesum, Jaap A., et al.
Publicado: (2023)

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
por: Mato, Anthony R., et al.
Publicado: (2020)

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
por: Visco, Carlo, et al.
Publicado: (2022)

Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection
por: Minniti, Caterina P., et al.
Publicado: (2021)

Circulating SARS-CoV-2(+) megakaryocytes are associated with severe viral infection in COVID-19
por: Fortmann, Seth D., et al.
Publicado: (2023)

Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity
por: Courjon, Johan, et al.
Publicado: (2021)

Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease
por: Mucalo, Lana, et al.
Publicado: (2021)

Reduced prevalence of SARS-CoV-2 infection in ABO blood group O
por: Barnkob, Mike Bogetofte, et al.
Publicado: (2020)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia
por: Karol, Seth E., et al.
Publicado: (2023)

Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
por: Adamkiewicz, Thomas V., et al.
Publicado: (2023)

Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones
por: Osman, Afaf E. G., et al.
Publicado: (2022)

Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study
por: Moore, John, et al.
Publicado: (2023)

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia
por: Ujjani, Chaitra, et al.
Publicado: (2022)

Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia
por: Engelmann, Robby, et al.
Publicado: (2023)

Improved outcomes of UM171–expanded cord blood transplantation compared with other graft sources: real-world evidence
por: Cohen, Sandra, et al.
Publicado: (2023)

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
por: Branagan, Andrew R., et al.
Publicado: (2021)

Early diagnosis of sickle cell disease at birth hospitals and vaccination centers in Angola using point-of-care tests
por: Olaniyan, Halimat S., et al.
Publicado: (2023)

Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant
por: Chung, David J., et al.
Publicado: (2022)

Under COVID of the night
por: Sekeres, Mikkael A.
Publicado: (2020)

Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity
por: Einarsdottir, Sigrun, et al.
Publicado: (2022)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
por: Quinn, Charles T., et al.
Publicado: (2022)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5hrttabeoohmb4rgr4v10qhhbt